Celgene's Pomalyst plus Velcade and dexamethasone meets in Phase III for MM

Celgene Corp. (NASDAQ:CELG) reported data from the open-label, international Phase III OPTIMISMM trial in about 559 patients

Read the full 178 word article

User Sign In